Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.450 +0.240 (+19.83%)
Streaming Delayed Price Updated: 12:43 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 897,732
Open 1.190
Bid (Size) 1.450 (15)
Ask (Size) 1.460 (4)
Prev. Close 1.210
Today's Range 1.190 - 1.530
52wk Range 0.9054 - 1.800
Shares Outstanding 54,978,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are experiencing notable movement on Wednesday?
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Discover the top movers in Wednesday's pre-market session.
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
+20.8%
+20.8%
1 Month
+16.9%
+16.9%
3 Month
+26.1%
+26.1%
6 Month
+33.0%
+33.0%
1 Year
+15.1%
+15.1%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
Via Benzinga
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars
Via Stocktwits
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Via Benzinga
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Via Benzinga
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
Via Benzinga
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire

Frequently Asked Questions

Is Vivani Medical, Inc. - Common Stock publicly traded?
Yes, Vivani Medical, Inc. - Common Stock is publicly traded.
What exchange does Vivani Medical, Inc. - Common Stock trade on?
Vivani Medical, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vivani Medical, Inc. - Common Stock?
The ticker symbol for Vivani Medical, Inc. - Common Stock is VANI on the Nasdaq Stock Market
What is the current price of Vivani Medical, Inc. - Common Stock?
The current price of Vivani Medical, Inc. - Common Stock is 1.450
When was Vivani Medical, Inc. - Common Stock last traded?
The last trade of Vivani Medical, Inc. - Common Stock was at 09/17/25 12:43 PM ET
What is the market capitalization of Vivani Medical, Inc. - Common Stock?
The market capitalization of Vivani Medical, Inc. - Common Stock is 79.72M
How many shares of Vivani Medical, Inc. - Common Stock are outstanding?
Vivani Medical, Inc. - Common Stock has 80M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.